Education
About Us
Working with TipRanks
Follow Us
Novartis (CH:NOVN)
:NOVN
NOVN Analyst Ratings
Moderate Buy
5 Buy
6 Hold
1 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
NOVN Stock 12 Month Forecast
Average Price Target
CHF102.63
▲(6.72%Upside)
| Highest Price TargetCHF115.00 | Average Price TargetCHF102.63 | Lowest Price TargetCHF89.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
TipRanks
CHF108
Buy
12.30%
Upside
Reiterated
05/22/25
Bank of America Securities
CHF111
Hold
15.42%
Upside
Reiterated
07/01/25
We update our forecast to 2Q25 EPS of $2.41 +22% above VA cons on sales $14.3bn, +15% above cons, with detailed variance provided overleaf. TRx trends for key products are strong, notably acceleration in growth for Kisqali (TRx +c94% YoY vs 1Q25 at +c86%, with continued strong adjuvant launch, we c12% ahead cons) and Scemblix (TRx +c124% YoY vs 1Q at +c110%, with continued strong launch in 1L CML, we c10% ahead cons), and continued strong TRx growth in other key drivers (Cosentyx/Kesimpta, both c5% ahead cons); 2) We are marginally above Entresto (+1% vs cons) and c6% below for Pluvicto; 3) Continued strong margin progression with 2Q at 41.0%, +143bps YoY. FY25 guide debates; Strong launches and Fx We see guide upside on product launches and Fx, with limited change as yet on generics.
Deutsche Bank
CHF115
Buy
19.58%
Upside
Reiterated
06/24/25
Berenberg Bank
CHF89
Hold
-7.46%
Downside
Reiterated
06/12/25
J.P. Morgan
―
Hold
―
Reiterated
06/02/25
Goldman Sachs
―
Hold
―
Reiterated
06/02/25
Bernstein
CHF115
Buy
19.58%
Upside
Reiterated
05/21/25
Barclays
CHF90
Sell
-6.42%
Downside
Reiterated
05/08/25
DZ BANK AG
―
Buy
―
Reiterated
04/30/25
Kepler Capital
CHF106
Buy
10.22%
Upside
Reiterated
04/29/25
Jefferies
CHF100
Hold
3.98%
Upside
Reiterated
04/29/25
Exane BNP Paribas
CHF95
Buy
-1.22%
Downside
Initiated
04/16/25
Morgan Stanley
CHF91
Sell
-5.38%
Downside
Initiated
02/12/25
Stifel Nicolaus
CHF109
Hold
13.34%
Upside
Reiterated
01/31/25
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
TipRanks
CHF108
Buy
12.30%
Upside
Reiterated
05/22/25
Bank of America Securities
CHF111
Hold
15.42%
Upside
Reiterated
07/01/25
We update our forecast to 2Q25 EPS of $2.41 +22% above VA cons on sales $14.3bn, +15% above cons, with detailed variance provided overleaf. TRx trends for key products are strong, notably acceleration in growth for Kisqali (TRx +c94% YoY vs 1Q25 at +c86%, with continued strong adjuvant launch, we c12% ahead cons) and Scemblix (TRx +c124% YoY vs 1Q at +c110%, with continued strong launch in 1L CML, we c10% ahead cons), and continued strong TRx growth in other key drivers (Cosentyx/Kesimpta, both c5% ahead cons); 2) We are marginally above Entresto (+1% vs cons) and c6% below for Pluvicto; 3) Continued strong margin progression with 2Q at 41.0%, +143bps YoY. FY25 guide debates; Strong launches and Fx We see guide upside on product launches and Fx, with limited change as yet on generics.
Deutsche Bank
CHF115
Buy
19.58%
Upside
Reiterated
06/24/25
Berenberg Bank
CHF89
Hold
-7.46%
Downside
Reiterated
06/12/25
J.P. Morgan
―
Hold
―
Reiterated
06/02/25
Goldman Sachs
―
Hold
―
Reiterated
06/02/25
Bernstein
CHF115
Buy
19.58%
Upside
Reiterated
05/21/25
Barclays
CHF90
Sell
-6.42%
Downside
Reiterated
05/08/25
DZ BANK AG
―
Buy
―
Reiterated
04/30/25
Kepler Capital
CHF106
Buy
10.22%
Upside
Reiterated
04/29/25
Jefferies
CHF100
Hold
3.98%
Upside
Reiterated
04/29/25
Exane BNP Paribas
CHF95
Buy
-1.22%
Downside
Initiated
04/16/25
Morgan Stanley
CHF91
Sell
-5.38%
Downside
Initiated
02/12/25
Stifel Nicolaus
CHF109
Hold
13.34%
Upside
Reiterated
01/31/25
Best Analysts Covering Novartis AG
1 Month
xxx
Success Rate
9/16 ratings generated profit
Average Return
+1.04%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 56.25% of your transactions generating a profit, with an average return of +1.04% per trade.
3 Months
xxx
Success Rate
17/24 ratings generated profit
Average Return
+3.24%
reiterated a xxx
rating 2 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 70.83% of your transactions generating a profit, with an average return of +3.24% per trade.
1 Year
Success Rate
22/24 ratings generated profit
Average Return
+9.93%
reiterated a buy rating 2 months ago
Copying David Evans's trades and holding each position for 1 Year would result in 91.67% of your transactions generating a profit, with an average return of +9.93% per trade.
2 Years
xxx
Success Rate
22/24 ratings generated profit
Average Return
+13.48%
reiterated a xxx
rating 2 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 91.67% of your transactions generating a profit, with an average return of +13.48% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
NOVN Analyst Recommendation Trends
Rating
Feb 25
Mar 25
Apr 25
May 25
Jun 25
Strong Buy
0
0
0
0
0
Buy
10
14
19
17
15
Hold
22
17
17
14
18
Sell
5
2
3
3
3
Strong Sell
0
0
0
0
0
total
37
33
39
34
36
Each month's total comprises the sum of three months' worth of ratings.
NOVN Financial Forecast
NOVN Stock Forecast FAQ
What is CH:NOVN’s average 12-month price target, according to analysts?
Based on analyst ratings, Novartis’s 12-month average price target is 102.63.
What is CH:NOVN’s upside potential, based on the analysts’ average price target?
Novartis has 6.72% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is Novartis a Buy, Sell or Hold?
Novartis has a consensus rating of Moderate Buy, which is based on 5 buy ratings, 6 hold ratings and 1 sell ratings.
What is Novartis’s share price target?
The average share price target for Novartis is 102.63. This is based on 12 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is CHF115.00 ,and the lowest forecast is CHF89.00. The average share price target represents 6.72% Increase from the current price of CHF96.17.
The highest analyst share price target is CHF115.00 ,and the lowest forecast is CHF89.00. The average share price target represents 6.72% Increase from the current price of CHF96.17.
What do analysts say about Novartis?
Novartis’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 12 Wall Streets Analysts.
How can I buy shares of Novartis?
To buy shares of CH:NOVN, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.